Nucl Med Mol Imaging.  2024 Aug;58(4):213-226. 10.1007/s13139-024-00842-9.

Radionuclide Imaging of the Neuroanatomical and Neurochemical Substrate of Cognitive Decline in Parkinson’s Disease

• Booth S
• Ko J

• KMID: 2558875
• DOI: http://doi.org/10.1007/s13139-024-00842-9

Abstract

Cognitive impairment is a frequent manifestation of Parkinson’s disease (PD), resulting in decrease in patients’ quality of life and increased societal and economic burden. However, cognitive decline in PD is highly heterogenous and the mechanisms are poorly understood. Radionuclide imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT) have been used to investigate the neurochemical and neuroanatomical substrate of cognitive decline in PD. These techniques allow the assessment of different neurotransmitter systems, changes in brain glucose metabolism, proteinopathy, and neuroinflammation in vivo in PD patients. Here, we review current radionuclide imaging research on cognitive deficit in PD with a focus on predicting accelerating cognitive decline. This research could assist in the development of prognostic biomarkers for patient stratification and have utility in the development of ameliorative or disease-modifying therapies targeting cognitive deficit in PD.

Keyword

Parkinson's disease; Cognitive decline; Positron emission tomography ; Single photon emission tomography; Prognosis